Glioblastoma

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1 clinical trial to evaluate SILEVERTINIB (BDTX-1535), an experimental drug intended to block a key growth signal in patients with recurrent high-grade glioma and newly diagnosed glioblastoma, driven by EGFR (Epidermal Growth Factor Receptor) genetic aberrations.

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1 clinical trial to evaluate GSK5764227, a B7-H3–targeted antibody-drug conjugate (ADC), in patients with recurrent grade 4 glioma (rGBM) and patients with brain metastases.

The Gliofocus Study is a global, open-label, randomized Phase 3 clinical trial sponsored by the Ivy Brain Tumor Center that will compare the efficacy of niraparib, a PARP1/2-selective inhibitor, versus temozolomide in adult patients with newly diagnosed MGMT unmethylated glioblastoma. 

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1 clinical trial to evaluate BMS-986504, an experimental drug intended to encourage anti-tumor activity in recurrent glioblastoma with MTAP deletion.